USA, Juvaris BioTherapeutics Announces First Close on $25M Series B Financing

Juvaris BioTherapeutics, a Burlingame, CA.-based biotechnology company developing adjuvanted vaccines for infectious diseases, completed the first close on its $25m Series B equity financing.
The round was led by SV Life Sciences with the participation of the existing investor Kleiner Perkins Caufield & Byers.
The funds will be used to advance Juvaris’ novel adjuvant platform of cationic-lipid DNA complexes, which are designed to improve the quality and quantity of immune responses achievable with vaccines. 
The Company is currently developing its lead adjuvant, JVRS-100, to improve the efficacy of seasonal influenza vaccines in the elderly population and vaccines for universal flu and pandemic flu. 

Join the discussion